Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Julie J Miller; L Nicolas Gonzalez Castro; Samuel McBrayer; Michael Weller; Timothy Cloughesy; Jana Portnow; Ovidiu Andronesi; Jill S Barnholtz-Sloan; Brigitta G Baumert; Mitchell S Berger; Wenya Linda Bi; Ranjit Bindra; Daniel P Cahill; Susan M Chang; Joseph F Costello; Craig Horbinski; Raymond Y Huang; Robert B Jenkins; Keith L Ligon; Ingo K Mellinghoff; L Burt Nabors; Michael Platten; David A Reardon; Diana D Shi; David Schiff; Wolfgang Wick; Hai Yan; Andreas von Deimling; Martin van den Bent; William G Kaelin; Patrick Y Wen

doi:10.1093/neuonc/noac207

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.

Authors

Julie J Miller^{1

2}, L Nicolas Gonzalez Castro^{2

3

4}, Samuel McBrayer⁵, Michael Weller⁶, Timothy Cloughesy⁷, Jana Portnow⁸, Ovidiu Andronesi^{2

9}, Jill S Barnholtz-Sloan¹⁰, Brigitta G Baumert¹¹, Mitchell S Berger¹², Wenya Linda Bi^{2

13}, Ranjit Bindra¹⁴, Daniel P Cahill¹⁵, Susan M Chang¹², Joseph F Costello¹², Craig Horbinski^{16

17

18}, Raymond Y Huang^{2

19}, Robert B Jenkins²⁰, Keith L Ligon^{2

21}, Ingo K Mellinghoff²², L Burt Nabors²³, Michael Platten²⁴, David A Reardon^{2

3

4}, Diana D Shi^{2

25}, David Schiff²⁶, Wolfgang Wick²⁷, Hai Yan²⁸, Andreas von Deimling²⁹, Martin van den Bent³⁰, William G Kaelin^{2

31}, Patrick Y Wen^{2

3

4}

Affiliations

¹ Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
⁵ Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, Texas, 75235, USA.
⁶ Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.
⁷ UCLA Neuro-Oncology Program, Los Angeles, CA, USA.
⁸ Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁹ Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
¹⁰ Informatics and Data Science (IDS), Center for Biomedical Informatics and Information Technology (CBIIT), Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Bethesda, MD, USA.
¹¹ Cantonal Hospital Graubunden, Institute of Radiation-Oncology, Chur, Switzerland.
¹² Department of Neurosurgery, University of California-San Francisco, San Francisco, California, USA.
¹³ Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
¹⁴ Department of Therapeutic Radiology, Brain Tumor Center, Yale School of Medicine, New Haven, CT, USA.
¹⁵ Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹⁶ Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
¹⁷ Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
¹⁸ Northwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
¹⁹ Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
²⁰ Individualized Medicine Research, Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, Minnesota 55901, USA.
²¹ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
²² Department of Neurology, Evnin Family Chair in Neuro-Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²³ Department of Neurology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
²⁴ CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
²⁵ Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
²⁶ Division of Neuro-Oncology, Department of Neurology, University of Virginia Health System, Charlottesville, Virginia, USA.
²⁷ Neuro-Oncology at the German Cancer Research Center (DKFZ), Program Chair of Neuro-Oncology at the National Center for Tumor Diseases (NCT), and Neurology and Chairman at the Neurology Clinic in Heidelberg, Heidelberg, Germany.
²⁸ Genetron Health Inc, Gaithersburg, Maryland 20879, USA.
²⁹ Department of Neuropathology, University Hospital Heidelberg, and, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and, DKTK, INF 224, 69120 Heidelberg, Germany.
³⁰ Brain Tumour Centre, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.
³¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Abstract

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.

Keywords: D-2HG; Isocitrate dehydrogenase (IDH); glioma.

MeSH terms

Adult
Brain Neoplasms* / diagnosis
Brain Neoplasms* / genetics
Brain Neoplasms* / therapy
Consensus
Glioma* / diagnosis
Glioma* / genetics
Glioma* / therapy
Humans
Isocitrate Dehydrogenase / genetics
Mutation

Substances

Isocitrate Dehydrogenase

Abstract

MeSH terms

Substances

Grants and funding